DrugPatentWatch Database Preview
Drugs in Development Information for MEDI4736
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug MEDI4736?
MEDI4736 is an investigational drug.
There have been 256 clinical trials for MEDI4736.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are twenty-three US patents protecting this investigational drug and seven hundred and seventy-eight international patents.
Summary for MEDI4736
| US Patents | 23 |
| International Patents | 778 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-09-06) |
| Vendors | 0 |
Recent Clinical Trials for MEDI4736
| Title | Sponsor | Phase |
|---|---|---|
| Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy | AstraZeneca | Phase 2 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | National Cancer Institute (NCI) | Phase 2 |
| DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | AstraZeneca | Phase 3 |
Clinical Trial Summary for MEDI4736
Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736
US Patents for MEDI4736
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MEDI4736 | Start Trial | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago (Chicago, IL) | Start Trial |
| MEDI4736 | Start Trial | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy | MedImmune Limited (Cambridge, GB) | Start Trial |
| MEDI4736 | Start Trial | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. (Menlo Park, CA) | Start Trial |
| MEDI4736 | Start Trial | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | AstraZeneca AB (Sodertalje, SE) | Start Trial |
| MEDI4736 | Start Trial | Apilimod for use in the treatment of renal cancer | LAM Therapeutics, Inc. (Guilford, CT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MEDI4736
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MEDI4736 | Canada | 2889182 | 2032-10-26 | Start Trial |
| MEDI4736 | European Patent Office | 2911669 | 2032-10-26 | Start Trial |
| MEDI4736 | World Intellectual Property Organization (WIPO) | 2014066834 | 2032-10-26 | Start Trial |
| MEDI4736 | Australia | 2015276173 | 2034-06-17 | Start Trial |
| MEDI4736 | Brazil | 112016028964 | 2034-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
